CeriBell, Inc. (NASDAQ:CBLL) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by Stanley Muller on Aug 31st, 2026

Shares of CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $22.40.

Several research analysts recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. BTIG Research boosted their price objective on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Barclays raised CeriBell to a “neutral” rating in a report on Tuesday, August 18th.

Read Our Latest Stock Report on CBLL

CeriBell Price Performance

CeriBell stock opened at $23.73 on Monday. The stock has a market capitalization of $910.76 million, a P/E ratio of -13.48 and a beta of 0.81. The company’s fifty day moving average price is $20.11 and its 200 day moving average price is $19.34. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell has a 1 year low of $10.85 and a 1 year high of $25.33.

CeriBell (NASDAQ:CBLL – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The company had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. As a group, equities research analysts anticipate that CeriBell will post -1.96 earnings per share for the current fiscal year.

Insider Transactions at CeriBell

In other news, CFO Scott Blumberg sold 33,512 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total transaction of $838,805.36. Following the completion of the sale, the chief financial officer owned 148,121 shares of the company’s stock, valued at $3,707,468.63. This represents a 18.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William W. Burke sold 2,207 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total transaction of $43,786.88. Following the completion of the sale, the director owned 23,022 shares of the company’s stock, valued at $456,756.48. This trade represents a 8.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 382,067 shares of company stock worth $8,025,866 in the last quarter. 17.70% of the stock is owned by insiders.

Hedge Funds Weigh In On CeriBell

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System raised its holdings in CeriBell by 409.5% in the 2nd quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock valued at $143,000 after acquiring an additional 5,909 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares during the last quarter. Formula Growth Ltd. purchased a new stake in shares of CeriBell in the second quarter valued at approximately $603,000. Bank of America Corp DE acquired a new stake in shares of CeriBell in the second quarter valued at approximately $4,619,000. Finally, PDT Partners LLC acquired a new stake in shares of CeriBell in the second quarter valued at approximately $1,026,000.

CeriBell Company Profile

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.